INSERM Université Paris-SaclayUnité Mixte de Recherche 1193VillejuifFrance.
Féderation Hospitalo-Universitaire Hépatinov, Hôpital Paul BrousseVillejuifFrance.
Hepatology. 2022 Apr;75(4):866-880. doi: 10.1002/hep.32211. Epub 2021 Dec 12.
Pluripotent stem cell-derived hepatocytes differentiated in monolayer culture are known to have more fetal than adult hepatocyte characteristics. If numerous studies tend to show that this immature phenotype might not necessarily be an obstacle to their use in transplantation, other applications such as drug screening, toxicological studies, or bioartificial livers are reliant on hepatocyte functionality and require full differentiation of hepatocytes. New technologies have been used to improve the differentiation process in recent years, usually evaluated by measuring the albumin production and CYP450 activity. Here we used the complex production and most importantly the activity of the coagulation factor IX (FIX) produced by mature hepatocytes to assess the differentiation of hemophilia B (HB) patient's induced pluripotent stem cells (iPSCs) in both monolayer culture and organoids.
Indeed, HB is an X-linked monogenic disease due to an impaired activity of FIX synthesized by hepatocytes in the liver. We have developed an in vitro model of HB hepatocytes using iPSCs generated from fibroblasts of a severe HB patient. We used CRISPR/Cas9 technology to target the genomic insertion of a coagulation factor 9 minigene bearing the Padua mutation to enhance FIX activity. Noncorrected and corrected iPSCs were differentiated into hepatocytes under both two-dimensional and three-dimensional differentiation protocols and deciphered the production of active FIX in vitro. Finally, we assessed the therapeutic efficacy of this approach in vivo using a mouse model of HB.
Functional FIX, whose post-translational modifications only occur in fully mature hepatocytes, was only produced in corrected iPSCs differentiated in organoids. Immunohistochemistry analyses of mouse livers indicated a good cell engraftment, and the FIX activity detected in the plasma of transplanted animals confirmed rescue of the bleeding phenotype.
在单层培养中分化的多能干细胞源性肝细胞已知具有比成人肝细胞更多的胎儿特征。如果许多研究倾向于表明这种不成熟表型不一定是将其用于移植的障碍,那么其他应用,如药物筛选、毒理学研究或生物人工肝脏,则依赖于肝细胞的功能,并且需要肝细胞的完全分化。近年来,已经使用新技术来改进分化过程,通常通过测量白蛋白产生和 CYP450 活性来评估。在这里,我们使用复杂的生产,最重要的是成熟肝细胞产生的凝血因子 IX(FIX)的活性,来评估乙型血友病(HB)患者的诱导多能干细胞(iPSC)在单层培养和类器官中的分化。
实际上,HB 是一种 X 连锁的单基因疾病,由于肝脏中肝细胞合成的 FIX 活性受损。我们使用来自严重 HB 患者成纤维细胞的 iPSC 开发了一种 HB 肝细胞的体外模型。我们使用 CRISPR/Cas9 技术靶向基因组插入凝血因子 9 小基因,该基因携带帕多瓦突变以增强 FIX 活性。未校正和校正的 iPSC 在二维和三维分化方案下分化为肝细胞,并在体外破译活性 FIX 的产生。最后,我们使用 HB 小鼠模型体内评估了这种方法的治疗效果。
只有在类器官中分化的校正 iPSC 才能产生仅在完全成熟的肝细胞中发生的翻译后修饰的功能性 FIX。对小鼠肝脏的免疫组织化学分析表明良好的细胞植入,并且在移植动物的血浆中检测到的 FIX 活性证实了出血表型的挽救。